Skip to main content
Erschienen in: Spektrum der Augenheilkunde 4-5/2016

01.10.2016 | original article

Long-term progression and risk factors in primary open-angle glaucoma in clinical care

verfasst von: Crenguţa Feraru, Dorin Chiseliţă, Anca Pantalon

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 4-5/2016

Einloggen, um Zugang zu erhalten

Summary

Purpose

The aim of the present study was to investigate the perimetric progression rate and associated risk factors in open-angle glaucoma in clinical practice.

Methods

This was a retrospective study based on clinical chart reviews of patients with primary open-angle glaucoma (POAG) followed up for more than 5 years with ≥5 SITA standard visual fields. Demographics, visual acuity (VA), central corneal thickness (CCT), intraocular pressure values (IOP), treatment (number of medications), visual fields (VFs), and associated systemic pathologies were recorded. Patients were followed up every 3–6 months and identical tests were performed. The VF progression rate was calculated as slope of mean deviation (MD) over time using the Glaucoma Progression Analysis software.

Results

In all, 69 eyes from 69 patients with POAG were included in the study and followed up for a mean period of 72.9 months (SD ± 31.7). The mean MD at the start was −4.4 dB (SD ± 6.0), with a mean number of VF tests of 8.3 (SD ± 2.9). The progression rate reached −0.18 ± 0.1 db/year. The mean IOP at all visits decreased over time from 18.2 mm Hg to 16.5 mm Hg (p < 0.05). A step-wise one-way ANOVA regression analysis concluded that for the MD slope the significant predictors were final MD level (R 2 = 0.126, p = 0.003) and a combination between baseline and final MD level (R 2 = 0.656, p = 0.000). Systemic factors such as sex, positive history of cardiovascular diseases, and hypertension reached no statistical relevance in terms of increased risk or significant association with glaucoma progression. Diabetes had a borderline significance (p = 0.07) as a “protective factor” against progression, as more “stable” cases were associated with diabetes than “progressing” ones.

Conclusion

The rate of VF changes in POAG correlated with and dependent on the baseline/final MD level; additional risk factors reached no statistical significance in our clinical care glaucoma study.
Literatur
1.
Zurück zum Zitat Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng C‑Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040. A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.CrossRefPubMed Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng C‑Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040. A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.CrossRefPubMed
2.
Zurück zum Zitat Heijl A, Buchholz P, Norrgren G, Bengtsson B. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol (Copenh). 2012;91(5):406–12.CrossRef Heijl A, Buchholz P, Norrgren G, Bengtsson B. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol (Copenh). 2012;91(5):406–12.CrossRef
3.
Zurück zum Zitat Aptel F, Aryal-Charles N, Giraud JM, el Cheheb H, Delbarre M, Chiquet C, Romanet JP, Renard JP. Progression of visual field in patients with primary open angle glaucoma – ProgF study 1. Acta Ophthalmol. 2015;93(8):e615–e620.CrossRefPubMed Aptel F, Aryal-Charles N, Giraud JM, el Cheheb H, Delbarre M, Chiquet C, Romanet JP, Renard JP. Progression of visual field in patients with primary open angle glaucoma – ProgF study 1. Acta Ophthalmol. 2015;93(8):e615–e620.CrossRefPubMed
4.
Zurück zum Zitat de Moraes CG, Liebmann J, Liebmann CA, Susanna R Jr, Tello C, Ritch R. Visual field progression oucomes in glaucoma subtypes. Acta Ophthalmol. 2013;91:288–93.CrossRefPubMed de Moraes CG, Liebmann J, Liebmann CA, Susanna R Jr, Tello C, Ritch R. Visual field progression oucomes in glaucoma subtypes. Acta Ophthalmol. 2013;91:288–93.CrossRefPubMed
5.
Zurück zum Zitat Forchheimer I, de Moraes CG, Teng CC, Folgar F, Tello C, Ritch R, Liebmann JM. Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye. 2011;25:626–32.CrossRefPubMedPubMedCentral Forchheimer I, de Moraes CG, Teng CC, Folgar F, Tello C, Ritch R, Liebmann JM. Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye. 2011;25:626–32.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat de Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R, Ritch R. Risk factors for visual field progression in treated glaucoma patients. Arch Ophthalmol. 2011;129:562–8.CrossRefPubMed de Moraes CG, Juthani VJ, Liebmann JM, Teng CC, Tello C, Susanna R, Ritch R. Risk factors for visual field progression in treated glaucoma patients. Arch Ophthalmol. 2011;129:562–8.CrossRefPubMed
7.
Zurück zum Zitat Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH. Rates of glaucomatous visual field change in a large clinical population. Invest Ophthalmol Vis Sci. 2014;55(7):4135–43.CrossRefPubMed Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH. Rates of glaucomatous visual field change in a large clinical population. Invest Ophthalmol Vis Sci. 2014;55(7):4135–43.CrossRefPubMed
8.
Zurück zum Zitat European Glaucoma Society. Terminology and guidelines for glaucoma, 3rd ed. Savona: Dogma; 2008, pp 138–41. ISBN 788887434286. European Glaucoma Society. Terminology and guidelines for glaucoma, 3rd ed. Savona: Dogma; 2008, pp 138–41. ISBN 788887434286.
9.
Zurück zum Zitat Leske MC, Heijl A, Hyman L, Bengsston B. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106(11):2144–53.CrossRefPubMed Leske MC, Heijl A, Hyman L, Bengsston B. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106(11):2144–53.CrossRefPubMed
10.
Zurück zum Zitat Rossetti L, Goni F, Denis P, Bengtsson B, Martinez A, Heijl A. Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review. Eye (Lond). 2010;24(Suppl 1):1–7.CrossRef Rossetti L, Goni F, Denis P, Bengtsson B, Martinez A, Heijl A. Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review. Eye (Lond). 2010;24(Suppl 1):1–7.CrossRef
11.
Zurück zum Zitat Folgar FA, de Moraes CG, Prata TS, et al. Glaucoma surgery decreases the rates of localized and global visual field progression. Am J Ophthalmol. 2010;149(2):258–64.CrossRefPubMed Folgar FA, de Moraes CG, Prata TS, et al. Glaucoma surgery decreases the rates of localized and global visual field progression. Am J Ophthalmol. 2010;149(2):258–64.CrossRefPubMed
12.
Zurück zum Zitat de Moraes CG, Ritch R, Liebmann JM. Bridging the major prospective national eye institute-sponsored glaucoma clinical trials and clinical practice. J Glaucoma. 2010;20:1–2.CrossRef de Moraes CG, Ritch R, Liebmann JM. Bridging the major prospective national eye institute-sponsored glaucoma clinical trials and clinical practice. J Glaucoma. 2010;20:1–2.CrossRef
13.
Zurück zum Zitat Prata TS, de Moraes CG, Teng CC, Tello C, Ritch R, Liebmann JM. Factors affecting rates of visual field progression in glaucoma patients with optic disc hemorhage. Ophthalmology. 2010;117:24–9.CrossRefPubMed Prata TS, de Moraes CG, Teng CC, Tello C, Ritch R, Liebmann JM. Factors affecting rates of visual field progression in glaucoma patients with optic disc hemorhage. Ophthalmology. 2010;117:24–9.CrossRefPubMed
14.
Zurück zum Zitat Bertrand V, Fieuws S, Stalmans I, Zeyen T. Rates of visual field loss before and after trabeculectomy. Acta Ophthalmol. 2014;92:116–20.CrossRefPubMed Bertrand V, Fieuws S, Stalmans I, Zeyen T. Rates of visual field loss before and after trabeculectomy. Acta Ophthalmol. 2014;92:116–20.CrossRefPubMed
15.
Zurück zum Zitat Choi YJ, Kim M, Park KH, Kim DM, Kim SH. The risk of newly developed visual impairment in treated normal tension glaucoma – a 10 year follow up. Acta Ophthalmol. 2014;92:e644–e649.CrossRefPubMed Choi YJ, Kim M, Park KH, Kim DM, Kim SH. The risk of newly developed visual impairment in treated normal tension glaucoma – a 10 year follow up. Acta Ophthalmol. 2014;92:e644–e649.CrossRefPubMed
16.
Zurück zum Zitat Rossetti L, Digiuni M, Montesano G, Centofanti M, Fea AM, Iester M, et al. Blindness and glaucoma: a multicenter data review from 7 academic eye clinics. PLOS ONE. 2015;10(8):e0136632–24.CrossRefPubMedPubMedCentral Rossetti L, Digiuni M, Montesano G, Centofanti M, Fea AM, Iester M, et al. Blindness and glaucoma: a multicenter data review from 7 academic eye clinics. PLOS ONE. 2015;10(8):e0136632–24.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Artes PH, O’Leary N, Nicolela MT, Chauhan BC, Crabb DP. Visual field progression in glaucoma: what is the specificity of the guided progression analysis? Ophthalmology. 2014;121(10):2023–7.CrossRefPubMed Artes PH, O’Leary N, Nicolela MT, Chauhan BC, Crabb DP. Visual field progression in glaucoma: what is the specificity of the guided progression analysis? Ophthalmology. 2014;121(10):2023–7.CrossRefPubMed
18.
Zurück zum Zitat Cioffi GA, Liebmann JM. Translating the OHTS results into clinical practice. J Glaucoma. 2002;11(5):375–7.CrossRefPubMed Cioffi GA, Liebmann JM. Translating the OHTS results into clinical practice. J Glaucoma. 2002;11(5):375–7.CrossRefPubMed
19.
Zurück zum Zitat Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965–72.CrossRefPubMed Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965–72.CrossRefPubMed
20.
Zurück zum Zitat Lee JM, Caprioli J, Nouri-Mahdavi K, Afifi A, Morales E, Ramanathan M, Yu F, Coleman AL. Baseline prognostic factors predict rapid visual field deterioration in glaucoma. Invest Ophthalmol Vis Sci. 2014;55(4):2228–36.CrossRefPubMed Lee JM, Caprioli J, Nouri-Mahdavi K, Afifi A, Morales E, Ramanathan M, Yu F, Coleman AL. Baseline prognostic factors predict rapid visual field deterioration in glaucoma. Invest Ophthalmol Vis Sci. 2014;55(4):2228–36.CrossRefPubMed
21.
Zurück zum Zitat Lee JM, Caprioli J, Nouri-Mahdavi K, Afifi A, Morales E, Ramanathan M, Yu F, Coleman A. Baseline prognostic factors predict rapid visual field deterioration in glaucoma. Invest Ophthalmol Vis Sci. 2014 Apr 7;55(4):2228–36. Lee JM, Caprioli J, Nouri-Mahdavi K, Afifi A, Morales E, Ramanathan M, Yu F, Coleman A. Baseline prognostic factors predict rapid visual field deterioration in glaucoma. Invest Ophthalmol Vis Sci. 2014 Apr 7;55(4):2228–36.
22.
Zurück zum Zitat Lichter PR, Musch DC, Gillespie BW. Interim clinical outcomes in the collaborative initial glaucoma study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–53.CrossRefPubMed Lichter PR, Musch DC, Gillespie BW. Interim clinical outcomes in the collaborative initial glaucoma study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–53.CrossRefPubMed
23.
Zurück zum Zitat De Moraes CG, Liebmann JM, Greenfield DS, et al. Risk factors for visual field progression in the low pressure glaucoma treatment study. Am J Ophtalmol. 2012;131:669–708. De Moraes CG, Liebmann JM, Greenfield DS, et al. Risk factors for visual field progression in the low pressure glaucoma treatment study. Am J Ophtalmol. 2012;131:669–708.
24.
Zurück zum Zitat Ernest PJ, Schouten JS, Beckers HJ. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013;120:512–9.CrossRefPubMed Ernest PJ, Schouten JS, Beckers HJ. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013;120:512–9.CrossRefPubMed
25.
Zurück zum Zitat Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–20, 829–830.CrossRefPubMed Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714–20, 829–830.CrossRefPubMed
26.
Zurück zum Zitat Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal tension glaucoma. Am J Ophthalmol. 2001;131:699–708.CrossRefPubMed Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal tension glaucoma. Am J Ophthalmol. 2001;131:699–708.CrossRefPubMed
27.
Zurück zum Zitat Kass MA, Heuer DK, Higginbotham EJ. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120(6):701–30.CrossRefPubMed Kass MA, Heuer DK, Higginbotham EJ. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol. 2002;120(6):701–30.CrossRefPubMed
28.
Zurück zum Zitat Choi J, Kook M. Systemic and ocular risk factors in glaucoma. New York: Hindawi, Biomed Research International; 2015, pp 1–9. Choi J, Kook M. Systemic and ocular risk factors in glaucoma. New York: Hindawi, Biomed Research International; 2015, pp 1–9.
29.
Zurück zum Zitat Wong VH, Bui BV, Vingrys AJ. Clinical and experimental links between diabetes and glaucoma. Clin Exp Optom. 2011;94(1):4–23, Clinical and experimental links between diabetes and glaucoma.CrossRefPubMed Wong VH, Bui BV, Vingrys AJ. Clinical and experimental links between diabetes and glaucoma. Clin Exp Optom. 2011;94(1):4–23, Clinical and experimental links between diabetes and glaucoma.CrossRefPubMed
30.
Zurück zum Zitat AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7, the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.CrossRef AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7, the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.CrossRef
31.
Zurück zum Zitat Kang JH, Loomis SJ, Rosner BA, Wiggs JL, Pasquale LR. Comparison of risk factor profiles for primary open-angle glaucoma subtypes defined by pattern of visual field loss: a prospective study. Invest Ophthalmol Vis Sci. 2015;56(4):2439–48.CrossRefPubMedPubMedCentral Kang JH, Loomis SJ, Rosner BA, Wiggs JL, Pasquale LR. Comparison of risk factor profiles for primary open-angle glaucoma subtypes defined by pattern of visual field loss: a prospective study. Invest Ophthalmol Vis Sci. 2015;56(4):2439–48.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Zhou M, Wang W, Huang W, Zhang X. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLOS ONE. 2014;9(8):e102972.CrossRefPubMedPubMedCentral Zhou M, Wang W, Huang W, Zhang X. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLOS ONE. 2014;9(8):e102972.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Gerber AL, Harris A, Siesky B, Lee E, Schaab TJ, Huck A, Amireskandari A. Vascular dysfunction in diabetes and glaucoma: a complex relationship reviewed. J Glaucoma. 2015;24(6):474–9.CrossRefPubMed Gerber AL, Harris A, Siesky B, Lee E, Schaab TJ, Huck A, Amireskandari A. Vascular dysfunction in diabetes and glaucoma: a complex relationship reviewed. J Glaucoma. 2015;24(6):474–9.CrossRefPubMed
34.
Zurück zum Zitat Shim SH, Kim CY, Kim JM, da Kim Y, Kim YJ, Bae JH, Sung KC. The role of systemic arterial stiffness in open-angle glaucoma with diabetes mellitus. Biomed Res Int. 2015;2015:425835.PubMedPubMedCentral Shim SH, Kim CY, Kim JM, da Kim Y, Kim YJ, Bae JH, Sung KC. The role of systemic arterial stiffness in open-angle glaucoma with diabetes mellitus. Biomed Res Int. 2015;2015:425835.PubMedPubMedCentral
35.
Zurück zum Zitat Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85–93.CrossRefPubMed Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85–93.CrossRefPubMed
36.
Zurück zum Zitat Abegão Pinto L, Willekens K, van Keer K, Shibesh A, Molenberghs G, Vandewalle E, Stalmans I. Ocular blood flow in glaucoma – the Leuven Eye Study. Acta Ophthalmol. 2016;94 doi:10.1111/aos.12962.PubMed Abegão Pinto L, Willekens K, van Keer K, Shibesh A, Molenberghs G, Vandewalle E, Stalmans I. Ocular blood flow in glaucoma – the Leuven Eye Study. Acta Ophthalmol. 2016;94 doi:10.​1111/​aos.​12962.PubMed
37.
Zurück zum Zitat Costa VP, Harris A, Anderson D, Stodtmeister R, Cremasco F, Kergoat H, Lovasik J, Stalmans I, Zeitz O, Lanzl I, Gugleta K, Schmetterer L. Ocular perfusion pressure in glaucoma. Acta Ophthalmol. 2014;92(4):e252–e266.CrossRefPubMed Costa VP, Harris A, Anderson D, Stodtmeister R, Cremasco F, Kergoat H, Lovasik J, Stalmans I, Zeitz O, Lanzl I, Gugleta K, Schmetterer L. Ocular perfusion pressure in glaucoma. Acta Ophthalmol. 2014;92(4):e252–e266.CrossRefPubMed
38.
Zurück zum Zitat Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Advanced Glaucoma Intervention of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114(11):1965–72.CrossRef Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Advanced Glaucoma Intervention of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114(11):1965–72.CrossRef
Metadaten
Titel
Long-term progression and risk factors in primary open-angle glaucoma in clinical care
verfasst von
Crenguţa Feraru
Dorin Chiseliţă
Anca Pantalon
Publikationsdatum
01.10.2016
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 4-5/2016
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-016-0315-8

Weitere Artikel der Ausgabe 4-5/2016

Spektrum der Augenheilkunde 4-5/2016 Zur Ausgabe

editorial

Editorial

Interview

Interview